Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer

Seminars in Oncology

Volumn 28, Issue 6 SUPPL. 18, 2001, Pages 43-47

  Hortobagyi, Gabriel N ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Box 424 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXEMESTANE; FULVESTRANT; GEMCITABINE; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; LEUPRORELIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0035680514     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(01)90108-3     Document Type: Review

References (52)

1. Progress in endocrine therapy for breast carcinoma
2. New horizons in treating metastatic disease
3. Developments in chemotherapy of breast cancer
4. Treatment of breast cancer
5. HER-2/neu oncogene amplification and expression in breast and ovarian cancers
6. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
7. Inhibition of human lung cancer cell line growth by an anti-p 185HER2 antibody
8. Oncogenes and growth factors in human lung cancer
9. Genetic changes in lung cancer
10. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: Correlation with poor prognosis
11. Overexpression of Her-2/neu in human prostate cancer and benign hyperplasia
12. HER-2/neu expression: A major prognostic factor in endometrial cancer
13. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
14. Phase la/lb trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu
15. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
16. Radiolabeled antibody targeting of the HER-2/neu oncoprotein
17. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: Comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods
18. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer
19. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185
20. Antisense oligodeoxynucleotides as therapeutic agents
21. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu
22. HER-2/neu-targeting gene therapy - A review
23. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
24. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel
25. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents
26. Farnesyl transferase inhibitors: Current developments and future perspectives
27. A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation
28. Inhibition of p38 MAP kinase as a therapeutic strategy
29. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
30. Ongoing phase II study of intravenous recombinant human anti-p185 HER2 monoclonal antibody 4D5 (MAb 4D5) in patients with stage IV breast cancer overexpressing HER2
31. Trastuzumab and capecitabine for metastatic breast cancer
32. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
33. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
34. Humanization of an anti-p185HER2 antibody for human cancer treatment
35. First-line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
36. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
37. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
38. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
39. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer
40. Final report: Weekly Herceptin and Taxol for metastatic breast cancer: Analysis of efficacy by HER2 immunophenotype (immunohistochemistry) and gene amplification (fluorescent in-situ hybridization)
41. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)
42. Weekly docetaxel and rhumabher2 combination therapy as first- or second-line treatment for metastatic breast cancer
43. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
44. HER-2/neu expression does not predict response to tamoxifen in ER-positive metastatic breast cancer
45. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients
46. Ongoing and planned adjuvant trials with trastuzumab
47. Herceptin and vinorelbine as second-line therapy for HER-2-positive metastatic breast cancer: A phase II study
48. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
49. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
50. Oncogene amplification and expression. Importance of methodologic considerations
51. The role of the HER-2 gene and its product in the management of primary and metastatic breast cancer
52. The concordance between the clinical trials assay and fluorescence in situ hybridization in the Herceptin pivotal trials